Cardiovascular disease (CVD) is a well-established co-morbidity of psoriasis, although
the precise unifying mechanisms remain unknown. The activity of T-cell populations
contribute to the expression of inflammatory cytokines and chemokines, endothelial
adhesion molecules, and other factors that underlie the psoriatic disease process
and also determine balances in lipid metabolism, cell trafficking, and angiogenesis.
Therefore, it has been proposed that abnormal T-cell activity may play a role in the
pathogenesis of both the psoriatic and atherosclerotic plaques [
[1]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Dermatological ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis.Exp. Dermatol. 2011; 20: 544-549
- CCL20 and IL22 messenger RNA expression after adalimumab vs methotrexate treatment of psoriasis: a randomized clinical trial.JAMA Dermatol. 2015; 151: 837-846
- Circulating lipocalin-2 and retinol-binding protein 4 are associated with intima-media thickness and subclinical atherosclerosis in patients with type 2 diabetes.PLoS One. 2013; 8: e66607
- IL-17A is essential for cell activation and inflammatory gene circuits in psoriasis.J. Allergy Clin. Immunol. 2012; 130: 145-154.e9
- IL-17 induces inflammation-associated gene products in blood monocytes and treatment with ixekizumab reduces their expression in psoriasis patient blood.J. Invest. Dermatol. 2014; https://doi.org/10.1038/jid.2014.268
- Psoriasis and systemic inflammatory diseases:potential mechanistic links between skin disease and co-morbid conditions.J. Invest. Dermatol. 2010; 130: 1785-1796
- Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways.J. Invest. Dermatol. 2011; 131: 1547-1558
- Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.J. Eur. Acad. Dermatol. Venereol. 2015; : 1128-1134
Vascular inflammation in psoriasis trial (the VIP trial (VIP). ClinicalTrials.gov Identifier: NCT01553058.
- Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).J. Thromb. Haemost. 2009; 7: 332-339
Article info
Publication history
Published online: March 08, 2016
Accepted:
March 7,
2016
Received in revised form:
March 2,
2016
Received:
November 3,
2015
Identification
Copyright
© 2016 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.
